Get the Stockscreener App
4.46
0.45%
0.02
After Hours:
4.37
-0.09
-2.02%
Lantern Pharma Inc stock is traded at $4.46, with a volume of 39,130.
It is up +0.45% in the last 24 hours and up +11.78% over the past month.
Lantern Pharma Inc is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Its proprietary AI and machine learning (ML) platform, RADR, uses oncology-focused data points and advanced ML algorithms to solve billion-dollar, real-world problems in cancer drug development. The group's growing pipeline of precision therapies has been accelerated using AI and input from world-class scientific advisors and collaborators.
See More
Previous Close:
$4.44
Open:
$4.42
24h Volume:
39,130
Relative Volume:
0.22
Market Cap:
$48.17M
Revenue:
-
Net Income/Loss:
$-19.25M
P/E Ratio:
-2.5056
EPS:
-1.78
Net Cash Flow:
$-17.87M
1W Performance:
+0.22%
1M Performance:
+11.78%
6M Performance:
-3.88%
1Y Performance:
+0.22%
1-Day Range:
$4.3243
$4.5999
1-Week Range:
$4.00
$4.8618
52-Week Range:
$2.55
$6.118
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
4.46 | 49.29M | 0 | -19.25M | -17.87M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
390.76 | 100.71B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.28 | 58.84B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
571.78 | 61.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
656.89 | 40.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
312.51 | 38.20B | 3.81B | -644.79M | -669.77M | -6.24 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
Lantern Pharma Launches AI Tool predictBBB.ai with 94% Accuracy for Blood-Brain Barrier Drug Development - citybuzz -
RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26 - Tri-City Herald
Will Lantern Pharma Inc. price bounce be sustainableJuly 2025 Summary & Safe Capital Preservation Plans - Newser
What does recent volatility data suggest for Lantern Pharma Inc.Market Activity Recap & Accurate Technical Buy Alerts - Newser
Key metrics from Lantern Pharma Inc.’s quarterly data2025 Growth vs Value & Weekly Chart Analysis and Trade Guides - Newser
Is Lantern Pharma Inc. meeting your algorithmic filter criteriaWeekly Stock Recap & High Return Stock Watch Alerts - Newser
Will a bounce in Lantern Pharma Inc. offer an exitTrend Reversal & Daily Technical Forecast Reports - Newser
Can swing trading help recover from Lantern Pharma Inc. lossesTreasury Yields & Smart Investment Allocation Insights - Newser
Published on: 2025-08-17 03:16:20 - Newser
Published on: 2025-08-17 02:12:31 - Newser
What institutional flow reveals about Lantern Pharma Inc.2025 Year in Review & Free Community Consensus Stock Picks - Newser
Analyzing Lantern Pharma Inc. with multi timeframe chartsTrade Volume Report & Verified Entry Point Signals - Newser
Can volume confirm reversal in Lantern Pharma Inc.2025 Fundamental Recap & Capital Protection Trade Alerts - Newser
Price momentum metrics for Lantern Pharma Inc. explainedMarket Movers & Safe Entry Point Alerts - Newser
Applying Wyckoff theory to Lantern Pharma Inc. stockInsider Buying & Free Verified High Yield Trade Plans - Newser
Advanced analytics toolkit walkthrough for Lantern Pharma Inc.2025 Top Decliners & Technical Confirmation Trade Alerts - Newser
Sectors Driving Future Growth for Lantern Pharma Inc. Stock2025 Breakouts & Breakdowns & Safe Entry Zone Tips - Newser
Does Lantern Pharma Inc. have strong EBITDA margins2025 EndofYear Setup & Weekly Hot Stock Watchlists - newsimpact.co.kr
Lantern Pharma secures EU patent for AI-driven cancer drug LP-284 - MSN
Lantern Pharma Inc. Recovery Likely Here’s What Data ShowsJuly 2025 Outlook & Daily Profit Focused Screening - sundaytimes.kr
Lantern Pharma shares fall 6.72% intraday despite positive clinical trial results. - AInvest
What is Lantern Pharma Inc.’s book value per share2025 Analyst Calls & Long Hold Capital Preservation Plans - newsyoung.net
Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses In Multiple Trials - Barchart.com
Lantern Pharma (NASDAQ: LTRN) Reports Q2 2025 Results, Achieves Complete Responses in Multiple Trials - The Globe and Mail
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates - BioSpace
Lantern Pharma Narrows Loss in Q2 - The Motley Fool
Lantern Pharma Narrows Loss in Q2 - Nasdaq
Lantern Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Lantern Pharma Reports Second Quarter 2025 Financial Results and Business Updates | LTRN Stock News - GuruFocus
What data driven models say about Lantern Pharma Inc.’s futureWeekly Trend Watch with Market Signals - Newser
Short Interest in Lantern Pharma Inc. (NASDAQ:LTRN) Rises By 109.5% - MarketBeat
Automated trading signals detected on Lantern Pharma Inc.Free Entry Points For Growing Stocks - Newser
Os Therapies Incorporated shares rise 1.14% intraday after Lantern Pharma's subsidiary cleared IND application for GBM trial. - AInvest
Lantern Pharma Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Lantern Pharma Inc. Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule - citybuzz -
Lantern Pharma (NASDAQ: LTRN) Launches AI Tool to Predict Efficacy of Cancer Drug Combinations - Barchart.com
Lantern Pharma (LTRN) Expected to Announce Quarterly Earnings on Thursday - Defense World
Lantern Pharma Announces Release of Advanced AI Module for Blood-Brain Barrier Permeability Prediction - AI Insider
Nerdy Inc. shares rise 1.78% after-hours following Lantern Pharma's FDA clearance for GBM trial. - AInvest
How Lantern Pharma Inc. stock performs during market volatilityDaily Stock Forecast Powered by AI Tools - Newser
Lantern Pharma (NASDAQ: LTRN) Subsidiary Starlight Therapeutics Cleared by FDA to Begin GBM Combination Trial - Barchart.com
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed - openPR.com
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed Clinical Trials And FDA-Approved Therapies Review By Delveinsight Dnatrix, Lantern Pharma, Vyriad, Chimerix, Pfizer, Takeda Pharmaceuticals - Menafn
Atypical Teratoid Rhabdoid Tumors Pipeline 2025: Detailed Clinical Trials and FDA-Approved Therapies Review by DelveInsight | DNAtrix, Lantern Pharma, Vyriad, Chimerix, Pfizer, Takeda Pharmaceuticals - Barchart.com
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial | LTRN Stock News - GuruFocus
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U - GuruFocus
Lantern Pharma's Subsidiary, Starlight Therapeutics, Announces U.S. Food and Drug Administration Clearance of IND for Phase Ib/2a Glioblastoma Multiforme (GBM) Trial - Business Wire
Lantern Pharma (NASDAQ: LTRN) Unveils AI Tool to Predict Blood-Brain Barrier Permeability with 94% Accuracy - Barchart.com
Lantern Pharma completes Japanese enrolment for lung cancer drug trial - Mugglehead Magazine
Lantern Pharma schließt japanische Rekrutierung für Lungenkrebsmedikamentstudie ab - Mugglehead Magazine
Real Time Chart Alerts Flash Bullish on Lantern Pharma Inc.Swing Trade Plans Emphasize Risk Management - metal.it
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lantern Pharma Inc Stock (LTRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kreis Leslie W. | 10% Owner |
Jun 13 '25 |
Sale |
3.09 |
40,000 |
123,600 |
49,957 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Fletcher Aaron G.L. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Kreis Leslie W. | 10% Owner |
Jun 12 '25 |
Sale |
3.38 |
60,647 |
204,987 |
51,860 |
| Kreis Leslie W. | 10% Owner |
Jun 11 '25 |
Sale |
3.40 |
950 |
3,230 |
54,746 |
| Kreis Leslie W. | 10% Owner |
Jun 10 '25 |
Sale |
3.40 |
16 |
54 |
54,791 |
| Fletcher Aaron G.L. | 10% Owner |
May 27 '25 |
Sale |
3.05 |
21,037 |
64,163 |
56,467 |
| Fletcher Aaron G.L. | 10% Owner |
May 29 '25 |
Sale |
3.03 |
20,200 |
61,206 |
54,792 |
| Fletcher Aaron G.L. | 10% Owner |
May 28 '25 |
Sale |
2.87 |
15,000 |
43,050 |
55,753 |
0.22%
3.58%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):